Hemostats Market Size, Share, Growth, and Industry Analysis, By Type (Thrombin-Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats, Gelatin Based Hemostats and Collagen Based Hemostats), By Application (Prehospital Treatment and Hospital Treatment), and Regional Forecast From 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMOSTATS MARKET OVERVIEW

The global Hemostats Market is estimated to be valued at approximately USD 3.43 Billion in 2026. The market is projected to reach USD 6.22 Billion by 2035, expanding at a CAGR of 6.7% from 2026 to 2035.North America holds ~40% share led by surgical procedure volumes, followed by Europe at ~30% and Asia-Pacific at ~25%. Growth is driven by increasing surgeries and trauma care demand.

With the growing number of chronic diseases, the past few years have witnessed a dramatic elevation in the number of surgical procedures performed. Hemostats find relevant applications in myriad healthcare domains which have led to an increasing awareness and enhanced performance of hemostats. The market is being steered by the escalating entry of new products having different formulations to address various conditions in the patients. The focus on scientific advancement has put much research and preference for nature-based ingredients to leverage their natural benefits. In addition, rising acceptance of biopolymers and nanoparticles in hemostats is also expected to increase the market value in the upcoming years.

An indispensable example of surgical agents hemostats are used for control of bleeding, that is to facilitate clotting in surgeries, which are gaining prominence in trauma cases, orthopedic surgery, cardiovascular procedures, and minimally invasive interventions because of ability to ensure rapid hemostasis and thus aid in surgical outcome. The demand for hemostats has been driven primarily by the increasing number of surgical procedures being performed around the globe, increasing incidence of trauma and accidents, and an ageing population, which are becoming extrinsically susceptible to chronic diseases requiring operative care.

KEY FINDINGS

• Market Size and Growth: Global Hemostats Market size is valued at USD 3.43 billion in 2026, expected to reach USD 6.22 billion by 2035, with a CAGR of 6.7% from 2026 to 2035.
• Key Market Driver: Rising surgical procedures contribute 46%, increasing trauma cases 33%, and adoption of advanced hemostatic products 29%
• Major Market Restraint: High product costs affect 37%, regulatory challenges impact 28%, and lack of skilled surgical training limits 25% of market potential.
• Emerging Trends: Use of bioactive hemostats represents 41%, combination products adoption 32%, and minimally invasive surgery integration 27% drive market innovation.
• Regional Leadership: North America holds 45%, Europe contributes 30%, Asia Pacific covers 20%, reflecting advanced healthcare infrastructure and surgical adoption rates.
• Competitive Landscape: Top five companies account for 52%, mid-tier players 33%, focusing on mergers, acquisitions, and innovative product pipelines worldwide.
• Market Segmentation: Thrombin-Based Hemostats 29%, Oxidized Regenerated Cellulose 22%, Combination Hemostats 18%, Gelatin Based 16%, Collagen Based 15%.
• Recent Development: Launch of absorbable hemostats increased 38%, and strategic collaborations with hospitals rose 27%, enhancing market reach and adoption.

GLOBAL CRISIS IMPACTING HEMOSTATS MARKET

Pandemic Caused Low Demand with Shifted Focus Towards Emergencies and COVID Patients

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

The postponements of elective surgeries in H1-2020 starkly declined the use of topical hemostats in orthopedics, general surgery, dental/maxillofacial, and cosmetic cases—the major demand drivers. In trauma, cardiovascular, and oncologic (urgent/essential) procedures, however, demand held up better for active (thrombin-based) and flowable hemostats. Access restrictions limited hospital vendors to in-person in-servicing and trials; this was therefore replaced by virtual education, remote proctoring, and a tightening of formulation controls. Hospitals had to give priority to ICU and COVID care: capital and formulary additions were slow; tender awards slipped; and price competition in commodity SKUs (e.g., oxidized cellulose, gelatin sponges) intensified.

LATEST TRENDS

Surging Technical Integration on Providing Effective Solutions to Groove Up the Market Growth

Modern machinery is designed to mimic the system inside the human body, functioning as an artificial substitute. The engineers at MIT are adding a two-component system which will clot blood at the site of internal injury when injected inside the body. The research is directed at nanoparticles made from PEG-PLGA, a biocompatible polymer, conjugated to the GRGDS peptide, and a polymer that mimics the action of fibrinogen in artificial clotting. Continuous upgrading and technological integration into the medical ecosystem are likely to drive the growth of the hemostats market during the forecast period. As this technology continues to develop, one may end up with next-generation combination hemostats that not only deliver effective hemostasis, but also target and achieve accurate clot formation at the molecular level.

• According to a U.S. National Institutes of Health (NIH)–indexed retrospective study, hemostatic agents were used in 30.3% (1,102,267 out of 3,633,799) major surgical procedures recorded in a national hospital database, with utilization increasing from 28.5% in 2000 to 35.2% in 2010 across general, orthopedic, and cardiothoracic surgeries. 

• Based on Premier Healthcare real-world utilization data, hemostatic agents are employed in approximately 1 out of every 3 minimally invasive surgeries worldwide, corresponding to ~36 million hemostatic units used in such procedures in 2024, highlighting the integration of these products in modern surgical practice. 

•   
•   
  

  Download Free Sample to learn more about this report

    

HEMOSTATS MARKET SEGMENTATION

By Type

On the differential basis of type, the market is sectioned into thrombin-based hemostats, oxidized regenerated cellulose based hemostats, combination hemostats, gelatin based hemostats and collagen based hemostats.

• Thrombin-Based Hemostats: These are drugs that accelerate the clotting cascade actively obtainable in bovine, human plasma-derived, or recombinant forms.

• Oxidized Regenerated Cellulose Based Hemostats: These are plant-based, absorbable mechanical hemostats; act as a physical matrix for clotting generally used in elective general surgeries, dental/maxillofacial, orthopedics.

• Combination Hemostats: It is the blend of a scaffold (gelatin/collagen/ORC) with thrombin or other actives; provides faster and stronger hemostasis generally used in complex surgeries.

• Gelatin Based Hemostats: It is a porcine/bovine-derived absorbable sponges, foams, powders used in general surgery, ENT, neurosurgery. Flexible handling.

• Collagen Based Hemostats: It is a bovine/porcine collagen matrix, highly absorbent and potent clot promoters generally used in orthopedic, cardiovascular, and dental surgeries.

By Application

On the differential basis of application bifurcation, the market is fragmented into prehospital treatment and hospital treatment.

• Prehospital Treatment: Emergency, trauma, military, and first responders will use hemostatic agents before reaching hospital admission. Smaller share but high growth potential; focused on emergency/trauma, military, and civilian EMS. More resilient during COVID.

• Hospital Treatment: Primary market for hemostats, used intraoperatively across a wide range of surgical specialties. Largest share of the market; hit hardest by elective procedure delays during COVID, but with strong recovery due to surgery backlog.

MARKET DYNAMICS

Market dynamics include driving and restraining factors, opportunities and challenges stating the market conditions.

Driving factor

Growing Volume of Surgical Procedures Performed to Multiply the Product Sales

The increase in surgical interventions can be attributed to the great prevalence of chronic and old age-related disorders all over the world. The elderly population is especially susceptible to illnesses including osteoporosis, arthritis, lumbar spinal stenosis (LSS), gastroesophageal reflux disease (GERD), and benign prostatic hyperplasia (BPH), which often demand surgical intervention to restore function or relieve pain. Moreover, patients suffering from arthritis and osteoporosis frequently show decreased bone density as well as vascular integrity, rendering them more prone to suffer significant hemorrhage following techniques such as joint arthroplasty or spinal surgeries. This is where hemostatic agents come into play: they become necessary to achieve rapid, effective hemostasis; thus, their use helps to minimize the risk of hematoma formation, surgical site infection, and prolonged operative time.

• According to CDC hospital surgical statistics, nearly 48 million surgical procedures are performed annually in the United States, creating substantial clinical need for effective intraoperative bleeding control with hemostatic products. 

• The World Health Organization (WHO) estimates that around 313 million surgeries are conducted globally each year, underscoring the scale of surgical demand and driving the use of hemostatic agents to manage perioperative bleeding worldwide. 

Expanded Minimal Invasive Surgeries to Incubate the Market Demand Globally

The hemostats market is increasingly propelled by the rapid acceleration of volumes for minimally invasive surgery (MIS). According to the International Society for Minimally Invasive Surgery, about 108 million laparoscopic, robotic, and endoscopic procedures are estimated to be performed globally by 2024—an approximate expansion of 11 million cases from 2022. Because trocar-based access limits visualization and prolongs coagulation time, a topical or flowable hemostat is now employed by surgeons in one out of three MIS cases: this translates into almost 36 million units this year. According to Premier Inc.'s real-time OR dashboard, robotic prostatectomies utilize an average of 1.4 hemostatic agents per case, compared to 0.8 in open counterparts—accounting for an extra 6.1 million units across urology alone. The larger US IDNs responded with a "lap-only" formulary: Kaiser Permanente added two sprayable thrombin sealants, with a negotiated ceiling of $68 per vial, with a committed minimum of 900,000 vials through 2026. Similar frameworks for bulk purchasing arose in Japan, Germany, and Gulf states, anchoring demand visibility for manufacturers for several years.

Restraining Factor

Adverse Ill Effects at Surgical Site has Taken Aback the Market Growth

Hemostatic agents, particularly biologic or animal-derived products, are usually associated with adverse effects, such as fibrosis, hypersensitivity reactions, protracted healing periods, and rarely, infections at the surgical site. Absorbable gelatin-based sponges, for example, are known to produce marked fibrotic reactions in tendon repair procedures, thereby possibly affecting tissue mobility. Localized inflammation or disruption of the tissue regeneration process can also result from incomplete absorption of residual hemostatic materials. These adverse events may complicate surgical procedures, prolong hospital stays, and ultimately affect physician confidence in particular product categories. The increased risks of adverse effects have also caused regulatory scrutiny and caution in using novel products, especially under financially constrained environments to refrain the hemostats market growth to show profitable outcomes.

• According to FDA adverse event reporting data, although absorbable hemostatic devices are used in millions of surgeries annually in the United States alone, safety reporting systems logged 165 device reports (including 8 deaths, 117 injuries, and 40 malfunctions) between 2003 and 2018 highlighting regulatory emphasis on appropriate use and monitoring. 

• NIH-indexed clinical data show that hemostatic agents were used in just 14% of approximately 430,000 hysterectomy procedures in a statewide U.S. analysis, indicating clinical practice variability and restraint in certain surgical contexts. 

Huge Adoption of Natural Products has Triggered Up the Market Growth

Opportunity

Natural polymers are being fused into synthetic polymers to enhance the quality of hemostatic agents, for instance, fibroin, which is a silk-derived protein, does not possess hemostatic quality because functional groups that promote clotting are absent.

Nevertheless, porous films formed through electrospinning silk fibroin can be co-processed with synthetic polymers to enhance the efficiency. In June 2023, Cresilon Inc., obtained approval from the U.S. FDA for their new Cresilon Hemostatic Gel (CHG)-composed of algal-derived polymers. With key companies continuing to bring forth novel and better solutions for the patients, the market for hemostats is anticipated to boom in size.

• According to NIH data on surgical trends, use of hemostatic agents increased across multiple procedures between 2000 and 2010; e.g., use in nephrectomy climbed from about 19.5% to 48.8%, and liver resection from 48.2% to 55.2% over that decade, reflecting growing clinical acceptance. 

• Premier Healthcare’s clinical database shows that robotic laparoscopic surgeries, such as prostatectomy, use an average of 1.4 hemostatic products per case versus 0.8 in open surgery signifying expanded adoption in advanced surgical approaches. 

Dearth of Skilled Personnels for Effective Utilization to Pose Challenges in the Market Growth

Challenge

The proper application of hemostatic devices can only be performed by trained personnel, since misuse such as an incomplete artery closure may lead to persistent hemorrhage or ischemic complications. Some hemostatic interventions are multi-step procedural techniques and therefore require specialized skills. Even with the devices proven to be effective at reducing blood loss, there is an evident shortage of skilled surgeons and operating room staff, be it in developed or developing regions.

Apart from that, as hemostatic technologies and clinical applications seem to advance rapidly, healthcare practitioners as a consequence must be constantly upgrading their own skills to ensure that these technologies are safe and effectively used. Even the most effective agents, when misapplied or underused, will not prove to be beneficial in a surgical environment.

• NIH-indexed utilization research reveals significant variation in hemostatic agent use among surgeons and hospitals, with usage rates in benign gynecologic procedures ranging from 10.9% up to 20.7% depending on provider practice patterns, suggesting clinical decision variability that challenges standardization. 

• According to NIH-indexed surgical data, although hemostats are used widely, they are significantly under-utilized in some surgeries (e.g., prostatectomy at 6.6%, hip arthroplasty at 7.3%) compared with high-usage procedures like spine surgery (82.2%) highlighting inconsistent application and associated procedural challenges. 

•   
•   
  Download Free Sample to learn more about this report

    

HEMOSTATS MARKET REGIONAL INSIGHTS

• North America

The Hemostats Market in North America is expected to hold the largest regional share through 2026–2035, capturing roughly 40 % of global revenues as a result of advanced healthcare infrastructure and consistently high volumes of surgical procedures across the United States and Canada. North America leads in the hemostats market share with the largest revenue contribution, which was about a quarter of share in 2024, mainly because of the sophisticated healthcare infrastructure, high per capita healthcare expenditure, and strong presence of major players in the market. The hemostats market in the United States was significant in 2023. Increased product demand is attributed to the high number of surgical interventions carried out in the U.S., especially within the orthopedics and cardiovascular surgery disciplines. For example, according to the American Joint Replacement annual report 2022, above 2.8 million knee and hip procedures were conducted in 2022 across the country's 50 states. This is just a sample of how extensive the surgical interventions done in the U.S. are and hence the resultant demand for hemostatic agents in the specialties.

• Asia Pacific

Asia Pacific is projected to account for about 25 % of the global hemostats market share over the 2026–2035 period, driven by expanding healthcare access, rising surgical intervention rates, and increasing investments in modern medical technologies across key markets such as China, Japan, and India. The hemostats market in Asia Pacific is set to have the fastest growth rate from 2024 to 2030, mainly due to the high population of that region, along with increasing health expenditure and the high demand for more advanced medical treatments & technologies. The increase in chronic disease occurrence and the growing need for specialized medical intervention add further impetus to Asia Pacific becoming a prime player in the future economic and healthcare improvements. More surgical procedures are done, and investments in medical technologies are enormous, which provide momentum for its growth. At the same time, startups and companies like Axio Biosolutions, which develop low-cost hemostats, would enhance the country's market share.

• Europe

Europe is anticipated to command approximately 30 % of the global hemostats market share between 2026 and 2035, supported by well‑established healthcare systems, growing demand for minimally invasive surgeries, and aging populations that contribute to sustained demand for bleeding control solutions.The hemostats market in Europe showed substantial growth resulting from the increasing elderly population and growing approvals from the European regulatory authority for hemostatic products. For instance, CE certification for CELOX PPH Uterine Hemostatic Tamponade from Medtrade Products Ltd. was awarded in November 2022. This product is beneficial in the rapid and effective control of postpartum bleeding. The UK hemostats market is expected to grow commendably at a significant CAGR over the forecast period owing to the rising number of surgical procedures being performed.

KEY INDUSTRY PLAYERS

Major Market Players Embrace Procurement Techniques to Remain Competitive

Market players are locked in in intense competition utilizing procedures such as item development, quality upgrade, competitive estimating, and successful branding. With shoppers progressively favoring economical items, these players are emphasizing the utilize of common and eco-friendly materials such as cotton and bamboo. They are particularly centering on propelling modern items custom fitted for unmistakable applications, tending to the different requests within the market. Moreover, there's a solid accentuation on improving delicateness and generally item quality.
A few market players are endeavoring to convey a sumptuous encounter through predominant plans and quality. Competitive techniques incorporate cost wars, advancements, and collaborations with retailers, all of which play significant parts in their market situating. Online nearness and client surveys hold expanding impact over customer choices. The market competition is multi-faceted, including item separation and key market situating. 

• Ethicon (a Johnson & Johnson subsidiary) - Products such as oxidized regenerated cellulose hemostats are included among hemostatic products widely used in U.S. surgical settings where ~48 million surgeries occur annually, positioning Ethicon’s devices within core clinical practices guided by CDC surgical activity data. 

• Pfizer - While not primarily a device maker, Pfizer’s involvement in hemostat-related biologics aligns with clinical practice guidelines that show hemostatic agent use increases from 28.5% to 35.2% over a decade in major surgeries, evidencing broader adoption of advanced hemostasis therapeutics. 

List of Hemostats Companies

• Ethicon (U.S.)
• Pfizer (U.S.)
• Baxter International Inc. (U.S.)
• R. Bard (U.S.)
• The Medicines Company (U.S.)
• Anika Therapeutics (U.S.)
• Advanced Medical Solutions (U.K.)
• Integra LifeSciences Corporation (U.S.)
• B Braun Melsungen AG (Germany)
• Gelita Medical GmbH (Germany)
• Equimedical (Netherlands)
• Vascular Solutions (U.S.)
• Marine Polymer Technologies (U.S.)
• Z-Medica, LLC (U.S.)
• CryoLife (U.S.)
• BioCer Entwicklungs-GmbH. (Germany)
• Biom'Up SAS (France)

KEY INDUSTRY DEVELOPMENTS

• July 2023: Baxter (US) launched its Absorbable Hemostatic PERCLOT powder in the USA. With this, the company is now able to give surgeons a comprehensive range of active and passive hemostatic products with applications towards bleeding control thereby optimizing the care of patients.

REPORT COVERAGE

The market is characterized by seriously competition, with various players competing for showcase share. The competitive scene incorporates a blend of built-up companies and rising new companies, each advertising a run of instruments with shifting highlights and capabilities. The showcase is driven by development, with companies ceaselessly improving their items to supply way better client involvement, more precise approval, and integration with other advancement apparatuses. The competitive competition is assisted escalates by the presence of both free and paid apparatuses, catering to distinctive fragments of clients.